Hospital
Saint Joseph Hospital, INC
Saint Joseph Hospital, INC was paid $12.01M by Medicaid between Jan 2018 and Dec 2024, across 91 billing codes. Its largest line is 99283, emergency room visit (moderate) — 44% of everything it billed.
33Billing provider infoSAINT JOSEPH HOSPITAL, INC
DENVER, CO 80218
DENVER, CO 80218
33aNPI1417946021assigned 10/17/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$12.01M
24GClaims407,082
24DCodes billed91
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Colorado
Rank by total paid#12 of 51
Median peer was paid$1.24M
This provider vs. median9.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 45,962 | $1.35M | |
| 2019 | 48,668 | $1.38M | |
| 2020 | 36,492 | $982K | |
| 2021 | 51,108 | $1.37M | |
| 2022 | 66,337 | $2.06M | |
| 2023 | 91,578 | $2.57M | |
| 2024incomplete | 66,937 | $2.30M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 44% | 43,155 | 37,852 | $5.25M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 40% | 46,793 | 39,930 | $4.83M |
| 80048 | Basic metabolic panel (calcium, ionized) | 4.3% | 43,461 | 35,167 | $516K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 3.8% | 4,999 | 4,168 | $460K |
| J3490 | Unclassified drugs | 2.6% | 131,086 | 54,664 | $316K |
| G0378 | Hospital observation service, per hour | <1% | 1,319 | 691 | $118K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 884 | 778 | $110K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 244 | 186 | $70K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 953 | 835 | $66K |
| 80053 | Comprehensive metabolic panel | <1% | 4,622 | 3,645 | $50K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 56,003 | 45,958 | $29K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 162 | 145 | $22K |
79 more codes
| S9445 | Patient education, not otherwise classified, non-physician provider, individual, per session | <1% | 443 | $20K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 105 | $19K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 89 | $17K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,513 | $13K |
| 36415 | Collection of venous blood by venipuncture | <1% | 7,390 | $13K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 13,954 | $9K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,353 | $8K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,374 | $8K |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 333 | $8K |
| 84484 | <1% | 1,654 | $7K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 42 | $6K |
| 80061 | Lipid panel | <1% | 758 | $4K |
| 84439 | <1% | 292 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 239 | $3K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 46 | $3K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 87 | $3K |
| G0432 | Infectious agent antibody detection by enzyme immunoassay (eia) technique, hiv-1 and/or hiv-2, screening | <1% | 324 | $2K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 53 | $2K |
| 86780 | <1% | 258 | $2K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 13 | $2K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,580 | $2K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $2K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 24 | $2K |
| 80076 | <1% | 654 | $2K | |
| 85027 | <1% | 342 | $1K | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 27 | $1K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 866 | $901.21 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 143 | $864.13 |
| 81001 | <1% | 3,558 | $849.91 | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,310 | $789.18 |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,442 | $759.06 |
| G0433 | Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening | <1% | 12 | $528.12 |
| 71046 | Radiologic examination, chest; 2 views | <1% | 627 | $458.44 |
| 87340 | <1% | 67 | $413.64 | |
| 86706 | <1% | 52 | $388.40 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 17 | $354.35 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 17 | $177.75 |
| 87428 | <1% | 307 | $154.70 | |
| 82550 | <1% | 1,304 | $138.04 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 14 | $132.24 |
| 82565 | <1% | 1,290 | $107.44 | |
| 86762 | <1% | 12 | $90.00 | |
| 80051 | <1% | 1,304 | $89.37 | |
| 84520 | <1% | 1,290 | $82.89 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 117 | $74.13 |
| 84703 | <1% | 153 | $66.14 | |
| 82728 | <1% | 14 | $56.20 | |
| 82947 | <1% | 1,382 | $39.10 | |
| 86850 | <1% | 12 | $37.00 | |
| 83690 | <1% | 766 | $27.43 | |
| 86900 | <1% | 12 | $18.50 | |
| 81003 | <1% | 290 | $12.20 | |
| 86901 | <1% | 12 | $9.30 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 3,871 | $4.48 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 701 | $1.12 |
| 82150 | 0% | 71 | $0.00 | |
| J2704 | Injection, propofol, 10 mg | 0% | 242 | $0.00 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 738 | $0.00 |
| 99214 | Doctor's office visit, returning patient (more involved) | 0% | 71 | $0.00 |
| 84075 | 0% | 28 | $0.00 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 0% | 46 | $0.00 |
| 82040 | 0% | 28 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 12 | $0.00 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 0% | 42 | $0.00 |
| 96376 | 0% | 15 | $0.00 | |
| 82247 | 0% | 28 | $0.00 | |
| J7030 | Infusion, normal saline solution , 1000 cc | 0% | 543 | $0.00 |
| 81025 | 0% | 260 | $0.00 | |
| J0136 | Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg | 0% | 91 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 54 | $0.00 |
| 84450 | 0% | 28 | $0.00 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 0% | 27 | $0.00 |
| 82977 | 0% | 28 | $0.00 | |
| 84460 | 0% | 28 | $0.00 | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 0% | 12 | $0.00 |
| 84155 | 0% | 28 | $0.00 | |
| 85610 | 0% | 14 | $0.00 | |
| 82248 | 0% | 17 | $0.00 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSTOEHR, TROY (VP OF FINANCE)
Parent organizationSCL HEALTH
| Provider | Location | Paid |
|---|---|---|
| Saint Joseph Hospital, INC | Denver, CO | $170K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.